First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T

Open source

DOI: 10.1016/j.esmoop.2021.100273
Published: 2021 Oct
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2021.100273,
  title = {First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.},
  author = {Reck M and Ciuleanu TE and Cobo M and Schenker M and Zurawski B and Menezes J and Richardet E and Bennouna J and Felip E and Juan-Vidal O and Alexandru A and Sakai H and Lingua A and Reyes F and Souquet PJ and De Marchi P and Martin C and Pérol M and Scherpereel A and Lu S and Paz-Ares L and Carbone DP and Memaj A and Marimuthu S and Zhang X and Tran P and John T},
  year = {2021},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2021.100273},
  url = {https://doi.org/10.1016/j.esmoop.2021.100273}
}

RIS

TY  - JOUR
TI  - First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.
AU  - Reck M
AU  - Ciuleanu TE
AU  - Cobo M
AU  - Schenker M
AU  - Zurawski B
AU  - Menezes J
AU  - Richardet E
AU  - Bennouna J
AU  - Felip E
AU  - Juan-Vidal O
AU  - Alexandru A
AU  - Sakai H
AU  - Lingua A
AU  - Reyes F
AU  - Souquet PJ
AU  - De Marchi P
AU  - Martin C
AU  - Pérol M
AU  - Scherpereel A
AU  - Lu S
AU  - Paz-Ares L
AU  - Carbone DP
AU  - Memaj A
AU  - Marimuthu S
AU  - Zhang X
AU  - Tran P
AU  - John T
PY  - 2021
JO  - ESMO open
DO  - 10.1016/j.esmoop.2021.100273
UR  - https://doi.org/10.1016/j.esmoop.2021.100273
ER  -

APA

M, R., TE, C., M, C., M, S., B, Z., J, M., E, R., J, B., E, F., O, J., A, A., H, S., A, L., F, R., PJ, S., P, D. M., C, M., M, P., A, S., S, L., L, P., DP, C., A, M., S, M., X, Z., P, T., & T, J. (2021). First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.. ESMO open. https://doi.org/10.1016/j.esmoop.2021.100273

Source records

pubmed · retrieved 2026-09-26T11:41:00.419Z